Medicines: Sacituzumab Govitecan

Sacituzumab govitecan in the treatment of metastatic urothelial carcinoma

Antibody-Drug Conjugates in TNBC: Sacituzumab Govitecan

The ASCENT of sacituzumab govitecan in metastatic TNBC | Aditya Bardia

Medicine Matters oncology

ASCENT: sacituzumab govitecan biomarker analysis

Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC

Final OS analysis of sacituzumab govitecan in TROPiCS-02

Efficacy of sacituzumab govitecan in mUC by Trop-2 expression

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC

TROPiCS-03: sacituzumab govitecan as a 2L treatment for ES-SCLC

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study

European Society for Medical Oncology (ESMO)

Oncotarget: Sacituzumab Govitecan in Triple-Negative Breast Cancer

Antibody-drug conjugates in advanced urothelial cancer: sacituzumab govitecan

Efficacy of sacituzumab govitecan by Trop-2 expression in patients with mUC

ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously tre...

Dr. Isaacs Discusses Sacituzumab Govitecan in TNBC

Sacituzumab Govitecan, a Novel Treatment for Patients with mTNBC

Onco'Zine - The International Oncology Network

Biomarker data point to wide use of sacituzumab govitecan in advanced TNBC | Sara Hurvitz

Medicine Matters oncology

ASCENT: sacituzumab govitecan shows promise in mTNBC patients